Publications by authors named "Lama Dawi"
Background Tumor fraction (TF) at liquid biopsy is a potential noninvasive marker for tumor burden, but validation is needed. Purpose To evaluate TF as a potential surrogate for tumor burden, assessed at contrast-enhanced CT across diverse metastatic cancers. Methods This retrospective monocentric study included patients with cancer and metastatic disease, with TF results and contemporaneous contrast-enhanced CT performed between January 2021 and January 2023.
View Article and Find Full Text PDFArticle Synopsis
- The 2023 SFR data challenge aimed to encourage researchers to create AI models for detecting pancreatic masses and determining if they are benign or malignant using abdominal CT scans.
- A total of 1,037 CT examinations were gathered from 18 French centers, organized into training and evaluation sets, with teams composed of radiologists, data scientists, and engineers participating in the analysis.
- The challenge involved 10 teams and showed promising results, with AI demonstrating potential in identifying pancreatic lesions from real data, although distinguishing between benign and malignant masses remains challenging.
Background: This retrospective study determined survival responses to immune checkpoint inhibitors (ICIs), comparing mono- (mono) and combo-immunotherapy (combo) in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) by analyzing quantitative imaging data and clinical factors.
Methods: One hundred fifty patients were included from two centers and divided into training (n = 105) and validation (n = 45) cohorts. Radiologists manually annotated chest-abdomen-pelvis computed tomography and calculated tumor burden.
Purpose: The objective of the study is to propose the immunotherapy progression decision (iPD) score, a practical tool based on patient features that are available at the first evaluation of immunotherapy treatment, to help oncologists decide whether to continue the treatment or switch rapidly to another therapeutic line when facing a progressive disease patient at the first evaluation.
Experimental Design: This retrospective study included 107 patients with progressive disease at first evaluation according to RECIST 1.1.